RGC
Regencell Bioscience Holdings Limited
$30.80
-2.92
(-8.66%)
Mkt Cap
15.23B
Volume
327,142
52W Range
0.66553-83.6
Sector
Healthcare
Beta
2.25
EPS (TTM)
-0.01
P/E Ratio
-2350.89
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (3.58M) | (4.30M) | (5.87M) | (7.42M) | (1.35M) | (812,371) | (390,990) |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow | (3.27M) | (4.01M) | (4.99M) | (6.05M) | (767,311) | (844,410) | (390,990) |
| FCF / Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 |
| Operating CF | (3.11M) | (4.00M) | (4.96M) | (5.27M) | (767,311) | (726,573) | (390,990) |
| Total Assets | 5.76M | 8.44M | 12.62M | 18.02M | 340,134 | 514,018 | 243,307 |
| Total Debt | 544,415 | 85,741 | 463,669 | 771,255 | 3.68M | 3.07M | 2.08M |
| Cash & Equiv | 2.42M | 2.96M | 1.56M | 6.42M | 59,413 | 386,979 | 243,307 |
| Book Value | 4.86M | 8.22M | 12.03M | 17.07M | (4.00M) | (2.65M) | (1.84M) |
| Return on Equity | -0.74 | -0.52 | -0.49 | -0.43 | N/A | N/A | N/A |
| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 | Q4 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | (2.34B) | 0 | 0 | 0 | 0 | 0 |
| Net Income | (1.73M) | (1.85M) | (1,117) | (1,033) | (2.65M) | (3.23M) | (3.94M) | (3.66M) | (506) | (166) | (257) | (149) |
| EPS | -0.00 | -0.14 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow | 0 | 0 | (2.00M) | (2.00M) | (2.50M) | (2.50M) | (3.02M) | (3.02M) | (189) | (194) | (238) | (184) |
| FCF / Share | N/A | N/A | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Operating CF | 0 | 0 | (2.00M) | (2.00M) | (2.48M) | (2.48M) | (2.63M) | (2.63M) | (196) | (186) | (204) | (158) |
| Total Assets | 5.76M | 7.48M | 8.44M | 10.48M | 12.62M | 15.55M | 18.02M | 21.06M | 340,134 | 600,374 | 514,018 | 0 |
| Total Debt | 544,415 | 0 | 85,741 | 0 | 463,669 | 0 | 771,255 | 1,363 | 3.68M | 3.54M | 3.07M | 0 |
| Cash & Equiv | 2.42M | 0 | 2.96M | 4.80M | 1.56M | 0 | 6.42M | 0 | 59,413 | 305,956 | 386,979 | (243,307) |
| Book Value | 4.86M | 6.72M | 8.22M | 10.16M | 12.03M | 14.66M | 17.07M | 19.70M | (4.00M) | (2.98M) | (2.65M) | (1.84M) |
| Return on Equity | -0.36 | -0.28 | -0.00 | -0.00 | -0.22 | -0.22 | -0.23 | -0.19 | N/A | N/A | N/A | N/A |
RGC News
RGC Resources, Inc. Declares Quarterly Dividend
Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now
Regencell Bioscience: Extended Lock-Up Creates Significant Upside Potential
Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
These 3 Growth Stocks Won't Be This Cheap Forever
RGC Resources, Inc. Reports First Quarter 2026 Earnings
UnitedHealth, Trade Desk, And Unity Are Among Top 10 Large Cap Losers Last Week (Jan. 26-Jan. 30): Are the Others in Your Portfolio?
RGC Resources, Inc. Schedules First Quarter 2026 Earnings Call
RGC Resources Holds Annual Shareholders Meeting